Review
Open access
Oct 2026
Transcriptional cyclin-dependent kinases as therapeutic targets in bone metastasizing cancers
The potential of CDK9 inhibition in bone metastases is explored, including effects on both tumor cell survival and RANKL-NF-κB -driven osteoclastogenic bone microenvironment, and how CDK12 and CDK13 may provide complementary or context-dependent therapeutic opportunities are discussed.
T. Kähkönen, Gergana Galabova, M. Thormann et al.
· Frontiers in Oncology · 0 citations